Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia
Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia
复制标题
DOI：
10.1038/sj.leu.2404287
复制
发表时间：
2006-08-01
期刊：
影响因子：
11.4
通讯作者：
Xu, W-L
中科院分区：
文献类型：
--
作者：
Jin, J.;Jiang, D-Z;Xu, W-L
评估HAA方案的疗效和毒性(同山梨碱4mg/m(2)/天，第1-3天；阿糖胞苷150mg/m(2)/天，第1-7天；阿克拉比星12mg /m(2)/day, days 1-7)作为诱导治疗新发急性髓系白血病（AML）的临床研究，纳入48例新诊断AML患者，年龄35（14-57）岁。中位随访时间为26个月。83%的患者达到完全缓解（CR），诱导HAA方案的第一个单疗程导致CR率为79%。在细胞遗传学良好、中等和不良的患者中，CR率分别为100,82和33%。对于所有达到CR的患者，从诱导治疗开始到评估缓解状态的中位时间为32天。对于所有患者，估计3年总生存率（OS）为53%，而对于M5患者，估计3年生存率为75%。与HAA方案相关的毒性是可以接受的，最常见的毒性是感染。本研究提示HAA方案可能是一种耐受性良好、有效的年轻成年AML患者诱导方案。
To assess the efficacy and toxicity of HAA regimen (homoharritonine 4mg/m(2)/day, days 1-3; cytarabine 150mg/m(2)/day, days 1-7; aclarubicin 12 mg/m(2)/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered into this clinical study. The median follow-up was 26 months. Eighty-three percent of patients achieved complete remission (CR), and the first single course of induction HAA regimen resulted in CR rate of 79%. The CR rate of 100, 82 and 33% were achieved in patients with favorable, intermediate and unfavorable cytogenetics, respectively. For all patients who achieved CR, the median time from the initiation of the induction therapy to the evaluation of the remission status was 32 days. For all patients, the estimated 3 years overall survival (OS) rate was 53%, whereas for patients with M5, the estimated OS rate at 3 years was 75%. The toxicities associated with HAA regimen were acceptable, and the most common toxicity was infection. This study suggested that HAA regimen might be a well-tolerable, effective induction regimen in young adult patients with AML.